Actinogen Medical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATGGF research report →
Price Chart
About the company
Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system.
- CEO
- Steven G. Gourlay
- IPO
- 2018
- Employees
- 6
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on ATGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $148.70M
- P/E
- -7.93
- PEG
- -0.08
- P/S
- 31.15
- P/B
- 17.52
- EV/EBITDA
- -8.29
- Div Yield
- 0.00%
- Gross Margin
- 96.16%
- Op Margin
- -365.31%
- Net Margin
- -326.26%
- ROE
- -134.14%
- ROIC
- -146.52%
Latest fiscal year · YoY change
- Revenue
- $5.49M-44.7%
- Gross Profit
- $5.49M-44.7%
- Op Income
- $-14,932,044
- Net Income
- $-14,732,263-12.9%
- EPS
- $-0.00+18.3%
- OCF Growth
- +55.4%
- FCF Growth
- +55.2%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.02
- Beta
- 0.89
- RSI (14)
- 50
- Avg Volume
- 819
No earnings-call transcripts are available for ATGGF yet.
- Free Float
- 82.2%
- Shares Outstanding
- 3.72B
- Float Shares
- 3.06B
Our ATGGF coverage
Recent articles, reports, and earnings notes.
No research on ATGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATGGF report →Riot Platforms $9.1B AI deal fuels speculation around Anthropic IPO
proactiveinvestors.com · Aug 11
Traders see little chance of Hormuz shipping recovery by end of August
proactiveinvestors.com · Aug 6
Hikma jumps 10% as brokers point to profit beat and undemanding rating
proactiveinvestors.com · Aug 6
Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results
proactiveinvestors.com · Aug 6
The Small Cap Watch: Healthcare, critical minerals and gold explorers advance projects
proactiveinvestors.com · Aug 6
Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI
proactiveinvestors.com · Aug 1
Novo Resources expands Wyloo silver targets - ICYMI
proactiveinvestors.com · Jul 24
Horizon Gold details A$1.31B Gum Creek NPV - ICYMI
proactiveinvestors.com · Jul 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.